Recent clinical studies of the effects of lipid-modifying therapies

American Journal of Cardiology

Volumn 110, Issue 1 SUPPL., 2012, Pages 15A-26A

  Gotto, Antonio M ^a   Moon, Jennifer E ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANACETRAPIB; ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RELEASE; DRUG TOLERABILITY; HEART PROTECTION; HUMAN; MONOTHERAPY; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK REDUCTION; SECONDARY PREVENTION;

EID: 84862239765     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2012.04.003     Document Type: Article

References (57)

1. S.M. Grundy, J.I. Cleeman, C.N.B. Merz, H.B. Brewer Jr, L.T. Clark, D.B. Hunninghake, R.C. Pasternak, S.C. Smith Jr, N.J. Stone Coordinating Committee of the National Cholesterol Education Program Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239 (Pubitemid 38924592)
2. P.M. Ridker, E. Danielson, F.A. Fonseca, J. Genest, A.M. Gotto Jr, J.J. Kastelein, W. Koenig, P. Libby, A.J. Lorenzatti, J.G. MacFadyen JUPITER Study Group Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
3. A. Keech, R.J. Simes, P. Barter, J. Best, R. Scott, M.R. Taskinen, P. Forder, A. Pillai, T. Davis, P. Glasziou FIELD study investigators Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial Lancet 366 2005 1849 1861
4. H.N. Ginsberg, M.B. Elam, L.C. Lovato, J.R. Crouse III, L.A. Leiter, P. Linz, W.T. Friedewald, J.B. Buse, H.C. Gerstein, J. Probstfield ACCORD Study Group Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 2010 1563 1574 Erratum in: N Engl J Med 2010;362:1748
5. M. Yokoyama, H. Origasa, M. Matsuzaki, Y. Matsuzawa, Y. Saito, Y. Ishikawa, S. Oikawa, J. Sasaki, H. Hishida, H. Itakura Japan EPA lipid intervention study (JELIS) Investigators Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis Lancet 369 2007 1090 1098 (Pubitemid 46483662)
6. J.C. LaRosa, S.M. Grundy, D.D. Waters, C. Shear, P. Barter, J.C. Fruchart, A.M. Gotto, H. Greten, J.J. Kastelein, J. Shepherd, N.K. Wenger Treating to New Targets (TNT) Investigators Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435 (Pubitemid 40471450)
7. T.R. Pedersen, O. Faergeman, J.J. Kastelein, A.G. Olsson, M.J. Tikkanen, I. Holme, M.L. Larsen, F.S. Bendiksen, C. Lindahl, M. Szarek, J. Tsai Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial JAMA 294 2005 2437 2445 (Pubitemid 41627921)
8. J. Armitage, L. Bowman, K. Wallendszus, R. Bulbulia, K. Rahimi, R. Haynes, S. Parish, R. Peto, R. Collins Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial Lancet 376 2010 1658 1669 Erratum in: Lancet 2011;377:126
9. W.E. Boden, J.L. Probstfield, T. Anderson, B.R. Chaitman, P. Desvignes-Nickens, K. Koprowicz, R. McBride, K. Teo, W. Weintraub AIM-HIGH Investigators Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy N Engl J Med 365 2011 2255 2267
10. K. Yokote, H. Bujo, H. Hanaoka, M. Shinomiya, K. Mikami, Y. Miyashita, T. Nishikawa, T. Kodama, N. Tada, Y. Saito Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: Collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study) Atherosclerosis 201 2008 345 352
11. E.M. Roth, J.M. McKenney, M.T. Kelly, C.M. Setze, D.M. Carlson, A. Gold, J.C. Stolzenbach, L.A. Williams, P.H. Jones Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study Am J Cardiovasc Drugs 10 2010 175 186
12. C.P. Cannon, S. Shah, H.M. Dansky, M. Davidson, E.A. Brinton, A.M. Gotto, M. Stepanavage, S.X. Liu, P. Gibbons, T.B. Ashraf Determining the Efficacy and Tolerability Investigators Safety of anacetrapib in patients with or at high risk for coronary heart disease N Engl J Med 363 2010 2406 2415
13. P.M. Ridker, N. Rifai, M. Clearfield, J.R. Downs, J.S. Weis, A.M. Gotto Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events N Engl J Med 344 2001 1959 1965 (Pubitemid 32568149)
14. P.M. Ridker, E. Danielson, F.A. Fonseca, J. Genest, A.M. Gotto, J.J. Kastelein, W. Koenig, P. Libby, A.J. Lorenzatti, J.G. MacFadyen JUPITER Trial Study Group Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuva-statin: a prospective study of the JUPITER trial Lancet 373 2009 1175 1182
15. R.J. Glynn, E. Danielson, F.A. Fonseca, J. Genest, A.M. Gotto, J.J. Kastelein, W. Koenig, P. Libby, A.J. Lorenzatti, J.G. MacFadyen A randomized trial of rosuvastatin in the prevention of venous thromboembolism N Engl J Med 360 2009 1851 1861
16. Crestor (rosuvastatin) [product information] 2011 AstraZeneca Wilmington, DE http://www1.astrazeneca-us.com/pi/crestor.pdf Accessed April 25, 2012
17. E.S. Spatz, M.E. Canavan, M.M. Desai From here to JUPITER: identifying new patients for statin therapy using data from the 1999-2004 National Health and Nutrition Examination Survey Circ Cardiovasc Qual Outcomes 2 2009 41 48
18. P. Libby, P.M. Ridker, G.K. Hansson Progress and challenges in translating the biology of atherosclerosis Nature 473 2011 317 325
19. S. Devaraj, U. Singh, I. Jialal The evolving role of C-reactive protein in atherothrombosis Clin Chem 55 2009 229 238
20. P. Elliott, J.C. Chambers, W. Zhang, R. Clarke, J.C. Hopewell, J.F. Peden, J. Erdmann, P. Braund, J.C. Engert, D. Bennett Genetic loci associated with C-reactive protein levels and risk of coronary heart disease JAMA 302 2009 37 48
21. C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC) Association between C reactive protein and coronary heart disease: mendelian randomization analysis based on individual participant data BMJ 342 2011 d548
22. S. Mora, R.J. Glynn, J. Hsia, J.G. MacFadyen, J. Genest, P.M. Ridker Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia Circulation 121 2010 1069 1077
23. M.A. Albert, R.J. Glynn, F.A.H. Fonseca, A.J. Lorenzatti, K.C. Ferdinand, J.G. MacFadyen, P.M. Ridker Race, ethnicity, and the efficacy of rosuva-statin in primary prevention: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial Am Heart J 162 2011 106 114
24. R.J. Glynn, W. Koenig, B.G. Nordestgaard, J. Shepherd, P.M. Ridker Rosuvastatin for primary prevention in older individuals with high C-reactive protein and low LDL levels: exploratory analysis of a randomized trial Ann Intern Med 152 2010 488 496
25. J. Hsia, J.G. MacFadyen, J. Monyak, P.M. Ridker Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dL with rosuvastatin J Am Coll Cardiol 57 2011 1666 1675
26. P.M. Ridker, J.G. MacFadyen, F.A. Fonseca, J. Genest, A.M. Gotto, J.J. Kastelein, W. Koenig, P. Libby, A.J. Lorenzatti, B.G. Nordestgaard JUPITER Study Group Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein Circ Cardiovasc Qual Outcomes 2 2009 616 623
27. R.A.H. Stewart Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk Future Cardiol 5 2009 231 236
28. N. Sattar, D. Preiss, H.M. Murray, P. Welsh, B.M. Buckley, A.J. de Craen, S.R. Seshasai, J.J. McMurray, D.J. Freeman, J.W. Jukema Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials Lancet 375 2010 735 742
29. Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis Lancet 371 2008 117 125
30. Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in14 randomised trials of statins Lancet 366 2005 1267 1278
31. M. De Lorgeril, P. Salen, J. Abramson, S. Dodin, T. Hamazaki, W. Kostucki, H. Okuyama, B. Pavy, M. Rabaeus Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal Arch Intern Med 170 2010 1032 1036
32. P.M. Ridker, R.J. Glynn The JUPITER trial: responding to the critics Am J Cardiol 106 2010 1351 1356
33. J.J. Brugts, T. Yetgin, S.E. Hoeks, A.M. Gotto, J. Shepherd, R.G. Westendorp, A.J. de Craen, R.H. Knopp, H. Nakamura, P. Ridker, R. van Domburg, J.W. Deckers The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials BMJ 338 2009 b2376
34. F. Taylor, K. Ward, T.H. Moore, M. Burke, G. Davey Smith, J.P. Casas, S. Ebrahim Statins for the primary prevention of cardiovascular disease Cochrane Database Syst Rev 2011 CD004816
35. J.R. Downs, M. Clearfield, S. Weis, E. Whitney, D.R. Shapiro, P.A. Beere, A. Langendorfer, E.A. Stein, W. Kruyer, A.M. Gotto Jr Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS Air Force/Texas Coronary Atherosclerosis Prevention Study JAMA 279 1998 1615 1622 (Pubitemid 28248586)
36. L.D. Lazar, M.J. Pletcher, P.G. Coxson, K. Bibbins-Domingo, L. Goldman Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era Circulation 124 2011 146 153
37. A.M. Gotto, J. Moon Pitavastatin for the treatment of primary hyperlipidemia and mixed dyslipidemia Exp Rev Cardiovasc Ther 8 2010 1079 1090
38. C. Johnson, D.D. Waters, D.A. DeMicco, A. Breazna, V. Bittner, H. Greten, S.M. Grundy, J.C. LaRosa Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeat revascularization in patients with previous percutaneous coronary intervention (post hoc analysis of the Treating to New Targets [TNT] Study) Am J Cardiol 102 2008 1312 1317
39. J. Shepherd, J.P. Kastelein, V.A. Bittner, R. Carmena, P.C. Deedwania, A. Breazna, S. Dobson, D.J. Wilson, A.L. Zuckerman, N.K. Wenger Treating to New Targets Steering Committee and Investigators Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease Mayo Clin Proc 83 2008 870 879
40. I. Holme, M. Szarek, N.B. Cater, O. Faergeman, J.J. Kastelein, A.G. Olsson, M.J. Tikkanen, M.L. Larsen, C. Lindahl, T.R. Pedersen Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL study Eur J Cardiovasc Prev Rehabil 16 2009 315 320
41. E. Link, S. Parish, J. Armitage, L. Bowman, S. Heath, F. Matsuda, I. Gut, M. Lathrop, R. Collins SEARCH Collaborative Group SLCO1B1 variants and statin-induced myopathy: a genomewide study N Engl J Med 359 2008 789 799
42. US Food and Drug Administration FDA Drug Safety Communication: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury June 8, 2011 http://www.fda.gov/Drugs/ DrugSafety/ucm256581.htm Accessed October 20, 2011
43. C. Baigent, L. Blackwell, J. Emberson, L.E. Holland, C. Reith, N. Bhala, R. Peto, E.H. Barnes, A. Keech, J. Simes, R. Collins Cholesterol Treatment Trialists' (CTT) Collaboration Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
44. D. Preiss, S.R.K. Seshasai, P. Welsh, S.A. Murphy, J.E. Ho, D.D. Waters, D.A. DeMicco, P. Barter, C.P. Cannon, M.S. Sabatine Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy JAMA 305 2011 2556 2564
45. M. Jun, C. Foote, J. Lv, B. Neal, A. Patel, S.J. Nicholls, D.E. Grobbee, A. Cass, J. Chalmers, V. Perkovic Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis Lancet 375 2010 1875 1884
46. R. Scott, R. O'Brien, G. Fulcher, C. Pardy, M. D'Emden, D. Tse, M.R. Taskinen, C. Ehnholm, A. Keech Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study Diabetes Care 32 2009 493 498
47. M. Matsuzaki, M. Yokoyama, Y. Saito, H. Origasa, Y. Ishikawa, S. Oikawa, J. Sasaki, H. Hishida, H. Itakura, T. Kita JELIS Investigators Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease Circ J 73 2009 1283 1290
48. P.M. Kris-Etherton, W.S. Harris, L.J. Appel Nutrition Committee AHA Scientific Statement: fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease Circulation 106 2002 2747 2757 (Pubitemid 35364932)
49. J.J. Kastelein, F. Akdim, E.S. Stroes, A.H. Zwinderman, M.L. Bots, A.F. Stalenhoef, F.L. Visseren, E.J. Sijbrands, M.D. Trip, E.A. Stein ENHANCE Investigators Simvastatin with or without ezetimibe in familial hypercholesterolemia N Engl J Med 358 2008 1431 1443 (Pubitemid 351482735)
50. A.B. Rosseb, T.R. Pedersen, K. Boman, P. Brudi, J.B. Chambers, K. Egstrup, E. Gerdts, C. Gohlke-Bärwolf, I. Holme, Y.A. Kesäniemi SEAS Investigators Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis N Engl J Med 359 2008 1343 1356
51. R. Peto, J. Emberson, M. Landray, C. Baigent, R. Collins, R. Clare, R. Califf Analyses of cancer data from three ezetimibe trials N Engl J Med 359 2008 1357 1366
52. T.C. Villines, E.J. Stanek, P.J. Devine, M. Turco, M. Miller, N.J. Weissman, L. Griffen, A.J. Taylor The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration J Am Coll Cardiol 55 2010 2721 2726
53. C. Baigent, M.J. Landray, C. Reith, J. Emberson, D.C. Wheeler, C. Tomson, C. Wanner, V. Krane, A. Cass, J. Craig SHARP Investigators The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial Lancet 377 2011 2181 2192
54. P.J. Barter, M. Caulfield, M. Eriksson, S.M. Grundy, J.J. Kastelein, M. Komajda, J. Lopez-Sendon, L. Mosca, J.C. Tardif, D.D. Waters ILLUMINATE Investigators Effects of torcetrapib in patients with high risk for coronary events N Engl J Med 357 2007 2109 2122 (Pubitemid 350146106)
55. J.G. Robinson Dalcetrapib: a review of phase II data Expert Opin Investig Drugs 19 2010 795 805
56. Z.A. Fayad, V. Mani, M. Woodward, D. Kallend, M. Abt, T. Burgess, V. Fuster, C.M. Ballantyne, E.A. Stein, J.C. Tardif dal-PLAQUE Investigators Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised trial Lancet 378 2011 1547 1559
57. Lüscher TF. Efficacy and safety of dalcetrapib in patients with or at risk of coronary heart disease-the dal-VESSEL trial. Presented at: European Society of Cardiology Congress 2011; August 28, 2011; Paris, France.